Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.390 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4
Open 1.390
Bid (Size) 1.340 (2)
Ask (Size) 1.540 (1)
Prev. Close 1.390
Today's Range 1.390 - 1.390
52wk Range 0.9400 - 2.550
Shares Outstanding 15,641,611
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
Via Investor Brand Network
Topics Intellectual Property

Performance

YTD
-2.1%
-2.1%
1 Month
-9.7%
-9.7%
3 Month
+20.9%
+20.9%
6 Month
-2.1%
-2.1%
1 Year
-21.9%
-21.9%

More News

Read More
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
Via Investor Brand Network
Topics Intellectual Property
NanoViricides Measles Drug Development Animal Study is Imminent
Via ACCESS Newswire
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention
Via AB Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
Via Investor Brand Network
Topics Intellectual Property
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
Via Investor Brand Network
Topics Intellectual Property
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
Via Investor Brand Network
Topics Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
Via Investor Brand Network
Topics Intellectual Property
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC
Via Investor Brand Network
Topics Intellectual Property
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present at D. Boral Capital Inaugural Global Conference
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387
Via Investor Brand Network
Topics Intellectual Property
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
Via ACCESS Newswire
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
Via Investor Brand Network
Topics Intellectual Property World Trade
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
Via Investor Brand Network
Topics Intellectual Property
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
Via Investor Brand Network
Topics Intellectual Property Regulatory Compliance

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?
Yes, NanoViricides, Inc. Common Stock is publicly traded.
What exchange does NanoViricides, Inc. Common Stock trade on?
NanoViricides, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for NanoViricides, Inc. Common Stock?
The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange
What is the current price of NanoViricides, Inc. Common Stock?
The current price of NanoViricides, Inc. Common Stock is 1.390
When was NanoViricides, Inc. Common Stock last traded?
The last trade of NanoViricides, Inc. Common Stock was at 07/02/25 08:00 PM ET
What is the market capitalization of NanoViricides, Inc. Common Stock?
The market capitalization of NanoViricides, Inc. Common Stock is 21.74M
How many shares of NanoViricides, Inc. Common Stock are outstanding?
NanoViricides, Inc. Common Stock has 22M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS